sSLAMF7 neutralization by elotuzumab reverses these effects, reducing the abundance of SLAMF7+ regulatory and exhausted T cells, and improving the immune landscape in relapsed/refractory MM. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.